Abstract
Neuroendocrine carcinoma (NEC) is a rare yet potentially perilous neoplasm. The objective of this study was to develop prognostic models for the survival of NEC patients in the genitourinary system and subsequently validate these models. A total of 7125 neuroendocrine neoplasm (NEN) patients were extracted. Comparison of survival in patients with different types of NEN before and after propensity score-matching (PSM). A total of 3057 patients with NEC, whose information was complete, were extracted. The NEC influencing factors were chosen through the utilization of the least absolute shrinkage and selection operator regression model (LASSO) and the Fine & Gary model (FGM). Furthermore, nomograms were built. To validate the accuracy of the prediction, the efficiency was verified using bootstrap self-sampling techniques and receiver operating characteristic curves. LASSO and FGM were utilized to construct three models. Confirmation of validation was achieved by conducting analyses of the area under the curve and decision curve. Moreover, the FGS (DSS analysis using FGM) model produced higher net benefits. To maximize the advantages for patients, the FGS model disregarded the influence of additional occurrences. Patients are expected to experience advantages in terms of treatment options and survival assessment through the utilization of these models.
Publisher
Public Library of Science (PLoS)
Reference27 articles.
1. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms;G Rindi;Endocr Pathol,2022
2. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know;A Couvelard;Best Pract Res Clin Endocrinol Metab
3. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma;A Ooki;Cancer Metastasis Rev,2023
4. Neuroendocrine Neoplasms of the Female Genitourinary Tract: A Comprehensive Overview;M Virarkar;Cancers (Basel),2022
5. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours;H Moch;Eur Urol,2022